Checking in on Big Pharma’s big immuno-oncology race

Alok Saboo FierceBiotech News

Boehringer Ingelheim, Eli Lilly can resubmit NDA for diabetes drug with warning letter resolved

Eric Palmer Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning ...

Eli Lilly gets on the trial transparency bandwagon

Damian Garde In keeping with changing industry standards, Eli Lilly has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all. FierceBiotech ...

Novartis nabs Merck exec Bruno Strigini to head up oncology business

Tracy Staton Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit. FiercePharma News

AbbVie’s leukemia drug program continues to wow analysts in early study

John Carroll AbbVie's experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 ...

GSK misses survival endpoint with Tykerb-Herceptin pairing

Carly Helfand Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve disease-free survival in HER2-positive early breast cancer patients ...

Lilly’s ramucirumab scores a marginal gain for lung cancer patients

John Carroll Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering ...

FDA will hear Sanofi’s second plea for Lemtrada approval

Emily Wasserman On Friday, the FDA accepted Sanofi's supplemental application for its once-rejected multiple sclerosis treatment Lemtrada for consideration, and a 6-month review ...
Page 3 of 3123
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS